{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:01:10Z","timestamp":1789992070858,"version":"4.0.1"},"reference-count":80,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T00:00:00Z","timestamp":1503360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006801","name":"Horace H. Rackham School of Graduate Studies, University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0181944","type":"journal-article","created":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T17:41:59Z","timestamp":1503423719000},"page":"e0181944","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":40,"title":["Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5455-3485","authenticated-orcid":true,"given":"Sibu P.","family":"Kuruvilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopinath","family":"Tiruchinapally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Colleen","family":"Crouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E. H.","family":"ElSayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan M.","family":"Greve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,8,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000367739","article-title":"Surgical and Locoregional Therapy of HCC: TACE","volume":"4","author":"M Tsurusaki","year":"2015","journal-title":"Liver Cancer"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.3748\/wjg.v11.i23.3644","article-title":"The value and limitation of transcatheter arterial chemoembolization in preventing recurrence of resected hepatocellular carcinoma","volume":"11","author":"H-Y Cheng","year":"2005","journal-title":"World J Gastroenterol"},{"key":"ref3","article-title":"Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone","author":"KT Brown","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3892\/ol.2011.469","article-title":"Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review)","volume":"3","author":"H Ueda","year":"2012","journal-title":"Oncol Lett"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1111\/j.1440-1746.2012.07276.x","article-title":"Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification","volume":"27","author":"D Miyaki","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3350\/cmh.2013.19.3.288","article-title":"Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy","volume":"19","author":"MJ Oh","year":"2013","journal-title":"Clin Mol Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L","article-title":"Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial","volume":"62","author":"CL Lai","year":"1988","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/86.9.700","article-title":"MDRl Gene Expression: Its Effect on Drug Resistance to Doxorubicin in Human Hepatocellular Carcinoma Cell Lines MDRl mRNA Expression of","volume":"86","author":"JG Park","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1021\/mp300249s","article-title":"BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo","volume":"9","author":"D-M Zhang","year":"2012","journal-title":"Mol Pharm"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1111\/bph.12055","article-title":"Targeted delivery of doxorubicin through conjugation with EGF receptor-binding peptide overcomes drug resistance in human colon cancer cells","volume":"168","author":"S Ai","year":"2013","journal-title":"Br J Pharmacol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.ajpath.2010.10.029","article-title":"Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model","volume":"178","author":"L Bao","year":"2011","journal-title":"Am J Pathol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/14622416.9.1.105","article-title":"ABC multidrug transporters: structure, function and role in chemoresistance","volume":"9","author":"FJ Sharom","year":"2008","journal-title":"Pharmacogenomics"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment","volume":"7","author":"M Volkova","year":"2011","journal-title":"Curr Cardiol Rev"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"S Zhang","year":"2012","journal-title":"Nat Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3348\/kjr.2009.10.5.425","article-title":"The Current Practice of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma","volume":"10","author":"SW Shin","year":"2009","journal-title":"Korean J Radiol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4318\/tjg.2013.0709","article-title":"Transarterial chemoembolization for treatment of hepatocellular carcinoma: A single center experience","volume":"24","author":"I Idilman","year":"2013","journal-title":"Turkish J Gastroenterol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/lt.23552","article-title":"Morbidity and Mortality Following Transarterial Liver Chemoembolization in Patients With Hepatocellular Carcinoma and Synthetic Hepatic Dysfunction","volume":"19","author":"E Garwood","year":"2013","journal-title":"Liver Transplant"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00270-012-0423-z","article-title":"Quality-improvement guidelines for hepatic transarterial chemoembolization","volume":"35","author":"A Basile","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1055\/s-2006-941442","article-title":"Complications of hepatic chemoembolization","volume":"23","author":"TWI Clark","year":"2006","journal-title":"Semin Intervent Radiol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Y Ichikawa","year":"2014","journal-title":"J Clin Invest"},{"key":"ref21","first-page":"567","article-title":"Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation","volume":"2","author":"AM Rahman","year":"2007","journal-title":"Int J Nanomedicine"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000265166","article-title":"Doxorubicin cardiomyopathy","volume":"115","author":"K Chatterjee","year":"2010","journal-title":"Cardiology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis","volume":"1","author":"SM Rafiyath","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1016\/j.biomaterials.2010.11.068","article-title":"N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers","volume":"32","author":"SH Medina","year":"2011","journal-title":"Biomaterials"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/adhm.201200406","article-title":"Targeting Hepatic Cancer Cells with PEGylated Dendrimers Displaying N\u2010Acetylgalactosamine and SP94 Peptide Ligands","volume":"2","author":"SH Medina","year":"2013","journal-title":"Adv Healthc Mater"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1016\/j.biomaterials.2013.02.070","article-title":"Enzyme-activated nanoconjugates for tunable release of doxorubicin in hepatic cancer cells","volume":"34","author":"SH Medina","year":"2013","journal-title":"Biomaterials"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1601046","DOI":"10.1002\/adhm.201601046","article-title":"N-Acetylgalactosamine-Targeted Delivery of Dendrimer-Doxorubicin Conjugates Influences Doxorubicin Cytotoxicity and Metabolic Profile in Hepatic Cancer Cells","volume":"6","author":"SP Kuruvilla","year":"2017","journal-title":"Adv Healthc Mater"},{"key":"ref28","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.113.003638","article-title":"Extracellular matrix-mediated maturation of human pluripotent stem cell-derived cardiac monolayer structure and electrophysiological function","volume":"9","author":"TJ Herron","year":"2016","journal-title":"Circ Arrhythmia Electrophysiol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1021\/cr900174j","article-title":"Dendrimers as carriers for delivery of chemotherapeutic agents","volume":"109","author":"SH Medina","year":"2009","journal-title":"Chem Rev"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1039\/b507350b","article-title":"Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates","author":"R Shukla","year":"2005","journal-title":"Chem Commun"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1021\/bm101046d","article-title":"Comparative biodistribution of PAMAM dendrimers and HPMA copolymers in ovarian-tumor-bearing mice","volume":"12","author":"S Sadekar","year":"2010","journal-title":"Biomacromolecules"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1021\/bm0506142","article-title":"PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality","volume":"7","author":"IJ Majoros","year":"2006","journal-title":"Biomacromolecules"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"16416","DOI":"10.1021\/am504849x","article-title":"Multifunctional lactobionic acid-modified dendrimers for targeted drug delivery to liver cancer cells: Investigating the role played by PEG spacer","volume":"6","author":"F Fu","year":"2014","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.1016\/S0005-2736(99)00192-3","article-title":"Effect of grafted polyethylene glycol (PEG) on the size, encapsulation efficiency and permeability of vesicles","volume":"1463","author":"AR Nicholas","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"9267","DOI":"10.1039\/c1sm05746d","article-title":"Mechanical properties of mushroom and brush poly(ethylene glycol)- phospholipid membranes","volume":"7","author":"S Kaufman","year":"2011","journal-title":"Soft Matter"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","article-title":"Challenges in development of nanoparticle-based therapeutics","volume":"14","author":"N Desai","year":"2012","journal-title":"AAPS J"},{"key":"ref37","first-page":"1886","article-title":"Lipid Complexes","volume":"3","author":"C V Kelly","year":"2010","journal-title":"Lipid Complexes"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"N Bertrand","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1021\/mp2005966","article-title":"Association of chemotherapeutic drugs with dendrimer nanocarriers: An assessment of the merits of covalent conjugation compared to noncovalent encapsulation","volume":"9","author":"LM Kaminskas","year":"2012","journal-title":"Mol Pharm"},{"key":"ref40","first-page":"3068","article-title":"Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin","volume":"25","author":"RG Gish","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"MER O\u2019Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"ref42","first-page":"4891","article-title":"Doxorubicin (75 mg\/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results","volume":"68","author":"R Chlebowski","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"AB Nair","year":"2016","journal-title":"J basic Clin Pharm"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrd4503","article-title":"A holistic approach to targeting disease with polymeric nanoparticles","volume":"14","author":"CJ Cheng","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1593\/neo.05469","article-title":"Lowering of Tumor Interstitial Fluid Pressure Reduces Tumor Cell Proliferation in a Xenograft Tumor Model 1","volume":"8","author":"M Hofmann","year":"2006","journal-title":"Neoplasia"},{"key":"ref46","first-page":"100","article-title":"Pharmaceutical Perspectives of Cancer Therapeutics","author":"T Seki","year":"2009"},{"key":"ref47","first-page":"289","article-title":"Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors","volume":"1","author":"H Sarin","year":"2011"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"25333","DOI":"10.1038\/srep25333","article-title":"Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes","volume":"6","author":"A Maillet","year":"2016","journal-title":"Sci Rep"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1161\/CIRCIMAGING.113.000899","article-title":"Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy a systematic review","volume":"6","author":"P Thavendiranathan","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12350-012-9512-2","article-title":"Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs","volume":"19","author":"RS Jiji","year":"2012","journal-title":"J Nucl Cardiol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/COC.0b013e31829e19be","article-title":"Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy","volume":"38","author":"MA Lunning","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"R685","DOI":"10.1152\/ajpregu.00082.2014","article-title":"Concomitant low-dose doxorubicin treatment and exercise","volume":"307","author":"K Sturgeon","year":"2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","article-title":"Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (\u2018hand-foot\u2019 syndrome)","volume":"18","author":"D Lorusso","year":"2007","journal-title":"Ann Oncol"},{"key":"ref54","first-page":"236","article-title":"C57BL\/6 mice are more appropriate than BALB\/C mice in inducing dilated cardiomyopathy with short-term doxorubicin treatment","volume":"28","author":"X Liu","year":"2012","journal-title":"Acta Cardiol Sin"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.taap.2016.09.012","article-title":"Sex-related differential susceptibility to doxorubicin-induced cardiotoxicity in B6C3F1 mice","volume":"310","author":"GR Jenkins","year":"2016","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.taap.2012.10.025","article-title":"Development of doxorubicin-induced chronic cardiotoxicity in the B6C3F1 mouse model","volume":"266","author":"VG Desai","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref57","first-page":"20","article-title":"Doxorubicin cardiotoxicity in the rat: an in vivo characterization","volume":"46","author":"R Hayward","year":"2007","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.acvd.2014.08.001","article-title":"Left ventricular performance is closely related to the physical properties of the arterial system: Landmark clinical investigations in the 1970s and 1980s","volume":"107","author":"JP M\u00e9rillon","year":"2014","journal-title":"Arch Cardiovasc Dis"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jpba.2015.10.026","article-title":"H1 NMR based metabolomic profiling revealed doxorubicin-induced systematic alterations in a rat model","volume":"118","author":"Q Niu","year":"2016","journal-title":"J Pharm Biomed Anal"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"H652","DOI":"10.1152\/ajpheart.2000.278.2.H652","article-title":"Developmental changes of cardiac function and mass assessed with MRI in neonatal, juvenile, and adult mice","volume":"278","author":"F Wiesmann","year":"2000","journal-title":"Am J Physiol\u2014Hear Circ Physiol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"R928","DOI":"10.1152\/ajpregu.00406.2001","article-title":"Chronic measurement of cardiac output in conscious mice","volume":"282","author":"B Janssen","year":"2002","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/mp800051m","article-title":"Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles","volume":"5","author":"F Alexis","year":"2008","journal-title":"Mol Pharm"},{"key":"ref63","first-page":"735","article-title":"PEGylation of nanoparticles improves their cytoplasmic transport","volume":"2","author":"J Suh","year":"2007","journal-title":"Int J Nanomedicine"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/03009734.2015.1064501","article-title":"Vascular permeability\u2014the essentials","volume":"120","author":"L Claesson-Welsh","year":"2015","journal-title":"Ups J Med Sci"},{"key":"ref65","first-page":"412","article-title":"Hepatic Microsomal Azoreductase Activity","volume":"22","author":"S Zbaida","year":"1994","journal-title":"Drug Metab Dispos"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1016\/S0021-9258(18)50676-1","article-title":"Rat liver cytosolic azoreductase purification and characterization","volume":"254","author":"M-T Huang","year":"1979","journal-title":"J Biol Chem"},{"key":"ref67","article-title":"Enzyme Systems that Metabolise Drugs and Other Xenobiotics","author":"S Zbaida","year":"2002"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","article-title":"Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration","volume":"14","author":"WF Richter","year":"2012","journal-title":"AAPS J"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0022-3565(25)28988-1","article-title":"The Route of Absorption of Intraperitoneally Administered Compounds","volume":"178","author":"D Brindle","year":"1971","journal-title":"J Pharmacol Exp Ther"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.bjc.6602394","article-title":"Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study","volume":"92","author":"JW Valle","year":"2005","journal-title":"Br J Cancer"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1008386822906","article-title":"A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma","volume":"11","author":"U Halm","year":"2000","journal-title":"Ann Oncol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/02841860600693473","article-title":"Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma","volume":"46","author":"PA Lind","year":"2007","journal-title":"Acta Oncol"},{"key":"ref73","first-page":"1892","article-title":"Effects of 90Y-microspheres on liver tumors: comparison of intratumoral injection method and intra-arterial injection method","volume":"41","author":"WY Lin","year":"2000","journal-title":"J Nucl Med"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3350\/kjhep.2011.17.2.120","article-title":"Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results","volume":"17","author":"JS Kim","year":"2011","journal-title":"Korean J Hepatol"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ejca.2008.10.039","article-title":"Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial","volume":"45","author":"H Richly","year":"2009","journal-title":"Eur J Cancer"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1471-2407-12-263","article-title":"The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma","volume":"12","author":"X-D Qu","year":"2012","journal-title":"BMC Cancer"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1634\/theoncologist.2011-0313","article-title":"Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial","volume":"17","author":"D Sansonno","year":"2012","journal-title":"Oncologist"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1007\/s10620-012-2136-1","article-title":"Sorafenib for the Treatment of Hepatocellular Carcinoma: A Systematic Review","volume":"57","author":"B Xie","year":"2012","journal-title":"Dig Dis Sci"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/MOG.0b013e3283383ca5","article-title":"Recent advances in the treatment of hepatocellular carcinoma","volume":"26","author":"AG Singal","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/1756283X09346669","article-title":"Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies","volume":"3","author":"SK Olsen","year":"2010","journal-title":"Therap Adv Gastroenterol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0181944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:50:14Z","timestamp":1750812614000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0181944"}},"subtitle":[],"editor":[{"given":"Nicola","family":"Amodio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,22]]},"references-count":80,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0181944","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,22]]}}}